Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
ID:
Password:
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

Agents/Distributors
 Regional Subscription Agents/Distributors
 
Current Topics in Pharmacology   Volumes    Volume 25 
Abstract
Comparative effect of valsartan versus valsartan-hydrochlorthiazide on the serum lipid profile in hypertensive patients
Zena Sattam Hamad, Sarraa Dhiaa Kasim, Eman Abdullah Sulaiman, Najlaa Saadi Ismael, Mohammed S. Almashhadany
Pages: 69 - 76
Number of pages: 8
Current Topics in Pharmacology
Volume 25 

Copyright © 2021 Research Trends. All rights reserved

ABSTRACT
 
The objective of this study is to investigate the impact of valsartan versus valsartan-hydrochlorothiazide on the lipid profile parameters in hypertensive patients in comparison with control. Healthy control and hypertensive patients of either sex participated in this study; they were assigned into three groups (of twenty-three subjects each). Group 1 was the control group. Group 2 comprised of hypertensive patients treated with valsartan and Group 3 comprised of hypertensive patients treated with valsartan-hydrochlorothiazide (valsartan-HCT) combination once a day with a dose of 80 mg or 160 mg and 80/12.5 mg or 160/12.5 mg or 160/25 mg (the duration was not less than 3 months), respectively. Blood samples were collected from each subject and then the parameters of the lipid profile were measured in both control and hypertensive patients using a biochemical analysis. Systolic and diastolic blood pressure in patients treated with valsartan and valsartan-HCT drugs were significantly higher than that of the control group. In treated groups, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and total cholesterol (TC) were significantly higher than those of the control group. However, in the valsartan-HCT group, high-density lipoprotein cholesterol (HDL-C) was significantly lower than that of the control group, while in the valsartan group, high-density lipoprotein cholesterol (HDL-C) was non-significantly lower than that of the control group. This study confirmed that the treatment with valsartan and valsartan-HCT may not control the blood pressure and that the drugs may interfere with lipid profile. Hence, a readjustment of the therapy is important.
View Full Article  


 
search


E-Commerce
Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Login
Search Products
Browse in Alphabetical Order : Journals
Series/Books
Browse by Subject Classification : Journals
Series/Books

Miscellaneous
Ordering Information Ordering Information
Downloadable forms Downloadable Forms